Zoledronic acid in the treatment of Paget's disease and other benign bone disorders

Expert Review of Endocrinology and Metabolism

Volumn 1, Issue 1, 2006, Pages 15-24

  Ringe, Johann D ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

bisphosphonate; bone resorption; clinical efficacy; osteoporosis; Paget's disease; prevention; safety; treatment; zoledronic acid

Indexed keywords

EID: 85008407196     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.1.1.15     Document Type: Article

References (50)

1. Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64 (11), 1197–1211 (2004).
2. Green JR. Bisphosphonates: preclinical review. Oncologist 9 (Suppl. 4), 3–13 (2004).
3. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J. Clin. Invest. 97 (12), 2692–2696 (1996).
4. Dunford JE, Thompson K, Coxon FP et al. Structure–activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2), 235–242 (2001).
5. Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) (In Press).
6. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9 (5), 745–751 (1994).
7. Binkley N, Kimmel D, Bruner J et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J. Bone Miner. Res. 13 (11), 1775–1782 (1998).
8. Glatt M. The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography. Eur. Cell Mater. 1, 18–26 (2001).
9. Gasser JA, Green JR. Zoledronic acid administered as a single intravenous dose preserves cancellous bone in ovariectomized rats without causing ‘frozen bone’. Bone 32 (5 Suppl. 1), S221 (2003).
10. Sims NA, Green JR, Glatt M et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis. Rheum. 50 (7), 2338–2346 (2004).
11. Herrak P, Gortz B, Hayer S et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis. Rheum. 50 (7), 2327–2337 (2004).
12. Aclasta Summary of Product Characteristics. Novartis Pharma. Basel, Switzerland (2004).
13. Siris ES, Roodman GD. Paget’s disease of Bone. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Fifth Edition. Favus MJ (Ed.), American Society for Bone and Mineral Research, DC, USA, 495–506 (2003).
14. Hosking DJ, Meunier PJ, Ringe JD, Reginster JY, Gennari C. Paget’s disease of bone: diagnosis and management. Br. Med. J. 312, 491–494 (1996).
15. Hosking D. Paget’s disease. In: Hosking D, Ringe JD (Eds), Treatment of Metabolic Bone Disease. Management Strategy and Drug Therapy. London, UK (2000).
16. Briesacher B, Orwig D, Seton M, Omar M, Kahler KH. Costs of treating Paget’s disease in a privately insured population. 27th Annual Meeting of the American Society for Bone and Mineral Research. TN, USA, September 23–27 2005.
17. Selby PL, Davie MWJ, Ralson SH, Stone MD. Guidelines on the management of Paget’s disease of Bone. Bone 31 (3), 10–19 (2002).
18. Delmas PD, Meunier PJ. The management of Paget’s disease of Bone. N. Engl. J. Med. 336 (8), 558–566 (1997).
19. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget’s disease of Bone. J. Bone Miner. Res. 16 (8), 1379–1387 (2001).
20. Gutteridge DH, Ward LC, Stewart GO et al. Paget’s disease: acquired resistance to one aminobisphosphonate with retained response to another. J. Bone Miner. Res. 14 (Suppl.2), 79–84 (1999).
21. Chung G, Keen RW. Zoledronate treatment in active Paget’s disease. Ann. Rheum. Dis. 62 (3), 275–276 (2003).
22. Arden-Cordone M, Siris ES, Lyles KW et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronic acid in Paget’s disease of Bone. Calcif. Tissue Int. 60 (5), 415–418 (1997).
23. Buckler H, Fraser W, Hosking D et al. Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study. Bone 24 (5 Suppl.), S81 –S85 (1999).
24. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases Type II collagen breakdown in patients with Paget’s disease of Bone. Bone 28 (5), 461–464 (2001).
25. Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N. Engl. J. Med. 353, 898–908 (2005).
26. Kuehn BM. Better osteoporosis management a priority. Impact predicted to soar with aging population. JAMA 293 (20), 2453–2458 (2005).
27. Cosman F. The prevention and treatment of osteoporosis: a review. Medscape Gen. Med. 7 (2), 1–22 (2005).
28. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (3), 271–287 (2004).
29. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346 (9), 653–661 (2002).
30. Jarrett S, Conaghan P, Sloan V et al. Evidence for symptomatic benefit of the nitrogen-containing bisphosphonate zoledronic acid (ZOL) in rheumatoid arthritis (RA). EULAR 2005. Vienna, Austria, 8–11 June (2005).
31. Jarrett S, Conaghan P, Papanastasiou P et al. Profound effect of zoledronic acid on bone mineral density in rheumatoid arthritis. EULAR 2004. Berlin, Germany, 9–12 June (2004).
32. Jarrett S, O’Connor P, Conaghan P et al. First evidence of structural benefit from a bisphosphonate, zoledronic acid, in rheumatoid arthritis. Ann. Rheum. Dis. 63 (Suppl. 1), 58 (2004).
33. Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R. Treatment of Gorham’s disease with zoledronic acid. Oral Oncol. 41 (7), 747–750 (2005).
34. Haas M, Leko-Mohr Z, Roschger P et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 63 (3), 1130–1136 (2003).
35. Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int. 65 (1), 304–309 (2004).
36. Poole K, Warburton E, Loveridge N, Rose C, Reeve J. Preserving hip bone mineral density following stroke using intravenous zoledronic acid: findings from a 1 year randomized controlled trial. Bone 34 (Suppl. 1), S95 –S96 (2004).
37. Shapiro JR, Beck TJ, Mustapha B, Ruff CB, Ballard P, Caminis J. Zoledronic acid counteracts bone loss in the spinal cord injury model of microgravity. J. Bone Miner. Res. 19 (Suppl. 1), S445 (2004).
38. Black DM, Rosario-Jansen T, Cauley JA et al. HORIZON-Pivotal Fracture Trial (PFT): unique design of a randomized, placebo-controlled trial to examine the effect of annual infusion of zoledronic acid on hip and spine fracture reduction. 31st European Symposium on Calcified Tissues. Nice, France, 5–9 June (2004).
39. Colon-Emeric CS, Caminis J, Suh TT et al. The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr. Med. Res. Opin. 20 (6), 903–910 (2004).
40. Hartl FC, Betchyk, Zhank J et al. Prevention of subsequent osteoporotic fractures after a hip fracture: the HORIZON-RFT study design and baseline data of subjects. 31st European Symposium on Calcified Tissues. Nice, France, 5–9 June (2004).
41. Mikulec KH, Delaney MF, Hurwitz S, LeBoff MS. Safety and efficacy of zoledronic acid: a chart review. J. Bone Miner. Res. 18(Suppl. 1), M321 (2003).
42. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353 (1), 99–102 (2005).
43. ADRAC Report. Bisphosphonates and osteonecrosis of the jaw. Med. J. Aust. 182 (8), 417–418 (2005).
44. Hoff AO, Toth B, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. 27th Annual Meeting of the American Society for Bone and Mineral Research. TN, USA, 23–27 September (2005), (Abstract 1218).
45. Siris ES. Paget’s disease of bone: treatment philosophy for the twenty-first century. Bone 24 (5), 55S –56S (1999).
46. Skugor M, Licata A. Osteoporosis. The Cleveland Clinic Disease Management Project www.clevelandclinicmeded.com/diseasemanagement/endocrinology/osteoporosis/osteoporosis1.htm
47. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact www.osteofound.org/press_centre/fact_sheet.html
48. ClinicalTrials.gov www.clinicaltrial.gov
49. Novartis eTrials. Osteoporosis Clinical Trial www.novartisclinicaltrials.com/etrials/DiseaseID33/Osteoporosis-clinical-trials.gov
50. The PRISM Trial www.paget.org.uk/prism.htm